Key facts
- This page summarizes Richard L. Eberly's Form 4 filing for CHEMBIO DIAGNOSTICS, INC..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 15 Mar 2022, 21:30.
Richard L. Eberly - 11 Mar 2022 Form 4 Insider Report for CHEMBIO DIAGNOSTICS, INC.
- Reporting relationship
- President and Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 11 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Mar 2022, 21:30:24 UTC
- Next SEC filing
- 01 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark L. Johnson, Attorney-in-Fact for Richard Eberly
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard L. Eberly filed Form 4 for CHEMBIO DIAGNOSTICS, INC. on 15 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CEMI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +432,000
- Change %
- Price
- $0.000000
- Shares after
- 432,000
- Date
- 11 Mar 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 432,000
- Exercise price
- Footnotes
- F1, F2
CEMI
transaction
Derivative
Incentive Stock Options
Award
- Transaction value
- $0
- Shares
- +143,067
- Change %
- Price
- $0.000000
- Shares after
- 143,067
- Date
- 11 Mar 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 143,067
- Exercise price
- $1.25
- Footnotes
- F3
CEMI
transaction
Derivative
Nonqualified Stock Options
Award
- Transaction value
- $0
- Shares
- +690,076
- Change %
- Price
- $0.000000
- Shares after
- 690,076
- Date
- 11 Mar 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 690,076
- Exercise price
- $1.25
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
On March 16, 2020, the reporting person was granted 432,000 restricted stock units scheduled to vest in equal installments on March 11 of each of 2023, 2024 and 2025, subject to continued service through each vesting date.
Footnote F3
The incentive stock options are scheduled to vest and become exercisable over four years, with two shares vesting on March 11, 2023, two shares vesting on March 11, 2024, two shares vesting on March 11, 2025 and the remaining 143,061 shares vesting on March 11, 2026, subject to continued service through each vesting date.
Footnote F4
The nonqualified stock options are scheduled to vest and become exercisable over four years, with one-fourth vesting on March 15, 2023, one-fourth vesting on March 11, 2024, one-fourth vesting on March 15, 2025 and the remaining one-fourth vesting on March 15, 2026, subject to continued service through each vesting date.
SEC remarks
President and Chief Executive Officer